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gram-negative bacillary BSI [6]. Of 8 patients in the study with
clinically significant BSIs, 88% had femoral and 62% had upper-
body VRE colonization. The temporal relationship between VRE
skin colonization and infection was not determined in the study,
and complete molecular typing information was not available;
however, the study results suggest that catheter-related VRE BSI
could result from skin colonization by the organism followed by
catheter hub colonization, similar to the pathogenesis of coagulase-
negative staphylococcal BSIs. Of 46 patients with VRE BSIs in
our study, 40 (87%) had a central venous catheter in place when
infection developed. Colonization of sites other than the gastroin-
testinal tract may be important in the development of VRE BSI.
The Medical Center at the University of California, San Fran-
cisco has shown a marked decline in oral vancomycin use from
1988 to 1994 [1], as have others [3]. However, deducing risk
factors for VRE acquisition using the ecologic data concerning
intravenous and oral vancomycin use [1] is problematic. Exposure
on an individual level may be similar, unrelated, or even opposite
to trends in vancomycin use on an institutional level. The absolute
number of grams of an antimicrobial used in a medical center may
bear little relationship to the risk of VRE colonization or infection
for an individual patient. Use of vancomycin and other antimicrobi-
als in oncology and intensive care units hospitalizing severely ill
patients at greatest risk of acquiring VRE may be more important.
In addition, a "case" of VRE was not defined by Luber et al.
Did these 3 patients have gastrointestinal colonization or clinical
infection? If cases were only colonized, then many other cases
may not have been detected if surveillance culturing was not rou-
tinely done. Last, colonization with VRE on admission does not
rule out previous nosocomial acquisition, as gastrointestinal" colo-
nization may be prolonged [7]. There may be multiple risk factors
for VRE acquisition; however, it is not possible to conclude that
oral vancomycin exposure is a risk factor for VRE colonization
Folinic Acid Supplements to Pyrimethamine-Sulfadiazine
for Toxoplasma Encephalitis Are Associated with Better
Outcome
To the Editor-Safrin et al. [1] described an increased risk of
therapeutic failure and death associated with the use of folinic acid
in conjunction with trimethoprim-sulfamethoxazole for treatment
of Pneumocystis carinii pneumonia (PCP) [1]. Folinic acid has
also been largely used to treat Toxoplasma encephalitis (TE) in
AIDS patients to reduce the hemotoxicity frequently associated
with high doses of sulfadiazine-pyrimethamine [2, 3].
To determine whether folinic acid influences the outcome of
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or infection on the basis of the apparently low prevalence of VRE
in one institution that has decreased usage of oral vancomycin.
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treatment of acute TE, we retrospectively reviewed the charts
of all patients with TE registered in the Swiss Human Immuno-
deficiency Virus Cohort Study from three centers (Geneva,
Lausanne, and Zurich) from July 1992 to December 1994. We
identified 130 cases of TE. Folinic acid had been given to 118
patients (91 %). Six patients died within 30 days of initiation
of TE therapy because of TE progression. Four of 12 patients
who did not receive folinic acid died compared with 2 «2% )
of 118 who received folinic acid (relative risk [RR] of death
associated with the absence of folinic acid, 19.7; 95% confi-
dence interval [CI], 4.0-96.5; P < .001). Complete response
to therapy was significantly associated with prescription of
folinic acid (80 of 118 patients vs. 3 of 12; RR of complete
response with folinic acid, 2.7; CI, 1.0-7.1; P == .008). A
change to less effective therapies and dose reduction because
ofhemotoxicity was less frequent in the group receiving folinic
acid (8 [70/0] of 118 vs. 5 [42%] of 12; RR, 6.1; CI, 2.4-15.8;
P == .002). Of the 4 patients who died and had not received
folinic acid supplements, none was receiving sulfadiazine-py-
rimethamine at time of death. Two switched drugs because of
hemotoxicity (to atovaquone and azithromycin) and 2 because
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of allergic skin reactions (to clindamycin-pyrimethamine).
One of the 2 patients who died and had received folinic acid
switched to clindamycin-pyrimethamine because of an allergic
skin reaction. All patients who had complete response to ther-
apy were receiving sulfadiazine-pyrimethamine (65 patients)
or clindamycin-pyrimethamine (18 patients).
In our retrospective study, in contrast with the results for PCP
[1], we found that folinic acid supplements were associated with
a better outcome (i.e., less mortality and higher proportions of
complete responses). This may be due to decreased hematologic
toxicity and, in tum, less need for dose reductions or changes to
less effective therapies. Folinic acid does not interfere with the
antitoxoplasmic effect of pyrimethamine or sulfadiazine because
of the absence of a membrane transport system for exogenous
folinic acid in Toxoplasma gondii [4]. In experimental murine
toxoplasmosis, survival increased when folinic acid was given with
pyrimethamine because of protection from the toxic effects of
pyrimethamine without interference with the action of the drug
against T. gondii [5, 6]. In the absence of a well-conducted prospec-
tive trial, we continue to recommend the use of folinic acid as an
adjuvant to pyrimethamine-sulfadiazine during treatment of acute
TE.
Christian Van Delden and Bernard Hirschel
Division of Infectious Diseases, University Hospital Geneva, Switzerland
References
1. Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-
sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients
is associated with an increased risk of therapeutic failure and death. J
Infect Dis 1994; 170:912-7.
2. Leport C, RaffiF, Matheron, et al. Treatment of central nervous system toxoplas-
mosis with pyrimethamine/sulfadiazine combination in 35 patients with the
acquired immunodeficiency syndrome. Am J Med 1988;84:94-100.
3. Boudes P, Zittoun J, Sobel A. Acute pancytopenia induced by pyrimethamine
during treatment of cerebral toxoplasmosis associated with AIDS. Role of
dihydrofolate reductase inhibitors. Ann Med Interne Paris 1990;141:183-6.
4. Niyongabo T, Leport C, Vilde JL. Folinic acid in cytopenia induced by
anti-parasitic drugs in AIDS patients. Presse Med 1991;20:1677-81.
5. Frenkel JK, Hitchings GH. Relative reversal by vitamins (p-aminobenzoic,
folic, and folinic acids) of the effects of sulfadiazine and pyrimethamine
on toxoplasma, mouse and man. Antibiot Chemother 1957; 7:630-8.
6. Giles CL, Jacobs L, Melton ML. Experimental use of folinic acid in the
treatment of toxoplasmosis with pyrimethamine. Ophthalmology
1964; 72:82-5.
